SCHEMBL1637150

SCHEMBL1637150

CCCN(CCC)CCCCN(CCC(=O)OCC)Cc1ccc(CN(Cc2ncc[nH]2)Cc2nccn2C)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.70
DRD2 P14416 1/20 0.35
POLB P06746 3/20 0.33
TSHR P16473 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
LTA4H P09960 2/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
NPC1 O15118 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12416881 0.94 CXCR4 (0.65) CXCR4DRD2POLBTSHRNPSR1
SCHEMBL15161927 0.94 CXCR4 (0.69) CXCR4LTA4HCTSD
SCHEMBL15257591 0.94 CXCR4 (0.69) CXCR4LTA4H
SCHEMBL15257588 0.94 CXCR4 (0.69) CXCR4KMT2ALTA4HCTSD
SCHEMBL1638391 0.93 CXCR4 (0.68) CXCR4ALDH1A1LTA4H
SCHEMBL2189962 0.93 CXCR4 (0.73) CXCR4DRD2POLBTSHRNPSR1
SCHEMBL1637867 0.93 CXCR4 (0.67) CXCR4DRD2CTSD
SCHEMBL1638094 0.92 CXCR4 (0.71) CXCR4DRD2POLBNPSR1KMT2A
SCHEMBL15162491 0.92 CXCR4 (0.69) CXCR4POLBLTA4HCTSD
SCHEMBL15257589 0.92 CXCR4 (0.66) CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US claimed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US claimed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP claimed
US-8722719-B2 Amine compound and use for same KUREHA CORPORATION (JP) 2014-05-13 US disclosed
US-8722719-B2 Amine compound and use for same KUREHA CORPORATION (JP) 2014-05-13 US disclosed
US-8722719-B2 Amine compound and use for same KUREHA CORPORATION (JP) 2014-05-13 US disclosed
EP-1724263-B1 BASIC AMINE COMPOUND AND USE THEREOF KUREHA CORP (JP) 2014-03-05 EP disclosed
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME KUREHA CORPORATION (JP) 2013-09-19 US disclosed
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME KUREHA CORPORATION (JP) 2013-09-19 US disclosed
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME KUREHA CORPORATION (JP) 2013-09-19 US disclosed
EP-2626349-A1 AMINE COMPOUND AND USE FOR SAME Kureha Corporation (JP) 2013-08-14 EP disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF KUREHA CORPORATION (JP) 2011-07-14 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-7932281-B2 Amine-based compound and use thereof KUREHA CORPORATION (JP) 2011-04-26 US disclosed
US-20070208007-A1 Amine-Based Compound and Use Thereof KUREHA CORPORATION (JP) 2007-09-06 US disclosed
EP-1724263-A1 BASIC AMINE COMPOUND AND USE THEREOF Kureha Corporation (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172212-A1 AMINE-BASED COMPOUND AND USE THEREOF NR0B2, NR5A2, NR1D2 CXCR4 86/4885DRD2 175/4885POLB 2350/4885
US-20130245280-A1 AMINE COMPOUND AND USE FOR SAME SAT1, ALDH7A1, HNMT CXCR4 4194/4885DRD2 829/4885POLB 4447/4885
US-20070208007-A1 Amine-Based Compound and Use Thereof NR0B2, NR5A2, NR2E1 CXCR4 100/4885DRD2 257/4885POLB 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.